ES2141330T3 - Monohidrato de (e)-2'-desoxi-2'-(fluorometileno)citidina. - Google Patents

Monohidrato de (e)-2'-desoxi-2'-(fluorometileno)citidina.

Info

Publication number
ES2141330T3
ES2141330T3 ES95907232T ES95907232T ES2141330T3 ES 2141330 T3 ES2141330 T3 ES 2141330T3 ES 95907232 T ES95907232 T ES 95907232T ES 95907232 T ES95907232 T ES 95907232T ES 2141330 T3 ES2141330 T3 ES 2141330T3
Authority
ES
Spain
Prior art keywords
fluorometilene
citidina
monohydrate
desoxi
ribonucleotida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95907232T
Other languages
English (en)
Inventor
Richard E Donaldson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2141330T3 publication Critical patent/ES2141330T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO MONOHIDRATO O (E)2''-DEOXI-2''-(FLUOROMETILENO)CITIDINA UTIL COMO INHIBIDOR DE REDUCTASA RIBONUCLEOTIDA EN EL TRATAMIENTO DE PACIENTES AQUEJADOS DE ESTADOS NEOPLASTICOS O ENFERMEDADES VIRALES.
ES95907232T 1994-01-07 1994-12-13 Monohidrato de (e)-2'-desoxi-2'-(fluorometileno)citidina. Expired - Lifetime ES2141330T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17895294A 1994-01-07 1994-01-07

Publications (1)

Publication Number Publication Date
ES2141330T3 true ES2141330T3 (es) 2000-03-16

Family

ID=22654587

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95907232T Expired - Lifetime ES2141330T3 (es) 1994-01-07 1994-12-13 Monohidrato de (e)-2'-desoxi-2'-(fluorometileno)citidina.

Country Status (20)

Country Link
EP (1) EP0738273B1 (es)
JP (1) JPH09511227A (es)
KR (1) KR100330328B1 (es)
CN (1) CN1043231C (es)
AT (1) ATE186732T1 (es)
AU (1) AU684604B2 (es)
CA (1) CA2179987C (es)
DE (1) DE69421721T2 (es)
DK (1) DK0738273T3 (es)
ES (1) ES2141330T3 (es)
FI (1) FI114396B (es)
GR (1) GR3032614T3 (es)
HU (1) HU217849B (es)
IL (1) IL112242A (es)
MX (1) MX9500363A (es)
NO (1) NO306409B1 (es)
NZ (1) NZ279030A (es)
TW (1) TW397838B (es)
WO (1) WO1995018815A1 (es)
ZA (1) ZA9512B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
KR100747106B1 (ko) 1999-05-11 2007-08-08 미쯔비시 가가꾸 가부시끼가이샤 퓨린 유도체 이수화물, 이를 유효성분으로 함유하는 의약및 이의 제조 중간체
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002648C (en) * 1988-11-15 2000-02-29 James R. Mccarthy 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
JPH0615557B2 (ja) * 1990-02-19 1994-03-02 ヤマサ醤油株式会社 ２’―デオキシ―２’―メチリデンシチジンの２水和物結晶
DK0640092T3 (da) * 1992-05-12 1996-12-30 Merrell Pharma Inc Fremgangsmåde til fremstilling af ribonucleotid-reduktaseinhibitorer

Also Published As

Publication number Publication date
GR3032614T3 (en) 2000-05-31
HU217849B (hu) 2000-04-28
NO306409B1 (no) 1999-11-01
MX9500363A (es) 1998-04-30
IL112242A0 (en) 1995-03-30
HUT75055A (en) 1997-03-28
CA2179987C (en) 1999-01-19
FI962769L (fi) 1996-07-05
WO1995018815A1 (en) 1995-07-13
EP0738273B1 (en) 1999-11-17
NO962848D0 (no) 1996-07-05
CA2179987A1 (en) 1995-07-13
JPH09511227A (ja) 1997-11-11
CN1043231C (zh) 1999-05-05
EP0738273A1 (en) 1996-10-23
DK0738273T3 (da) 2000-04-17
NZ279030A (en) 1997-05-26
DE69421721D1 (de) 1999-12-23
IL112242A (en) 2000-08-31
TW397838B (en) 2000-07-11
KR100330328B1 (ko) 2002-12-05
AU1553295A (en) 1995-08-01
FI962769A0 (fi) 1996-07-05
DE69421721T2 (de) 2000-04-27
AU684604B2 (en) 1997-12-18
HU9601848D0 (en) 1996-09-30
NO962848L (no) 1996-09-06
CN1141045A (zh) 1997-01-22
ZA9512B (en) 1995-09-11
ATE186732T1 (de) 1999-12-15
FI114396B (fi) 2004-10-15

Similar Documents

Publication Publication Date Title
ES2191102T3 (es) Heterociclos de peptidilo utiles en el tratamiento de las afecciones relacionadas con la trombina.
GB0108592D0 (en) Therapeutic agents
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
DE69925133D1 (de) Pyrrolobenzodiazepine
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
BRPI0413449A (pt) compostos de quinoxalina
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
BR9812837A (pt) Processo para fazer um composto, e, composto
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
DK1296671T3 (da) Gabapentinanaloger til sövnforstyrrelser
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
BR9804027A (pt) Novos beta-ceto ésteres
BR0111892A (pt) Bis-arilsulfonas
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
FI962769A0 (fi) (E)-2'-deoksi-2'(fluorimetyleeni)sytidiinin monohydraatti
SE9801494D0 (sv) Novel use
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
NO20005548L (no) Mykobakterieinhibitorer
HRP20050534A2 (en) Prevention and treatment of alzheimer's disease

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 738273

Country of ref document: ES